The Medicines Co.’s FDA-rejected cardio drug finds EU success

Damian Garde

European regulators are recommending approval for The Company's cangrelor, setting up an overseas nod for a blood-thinning rejected by the FDA last year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS